Lawyers for the plaintiffs allege that Novo Nordisk negligently failed to adequately warn of such potential side effects, or caution patients that Ozempic has been approved by food and drug government regulators only as a treatment for patients suffering from diabetes and has not been approved by such regulators for weight loss purposes only. Lawyers also allege liability under product liability law. Prescriptions by doctors for Ozempic for weight loss purposes have increased dramatically over the past 5 years as the drug has been promoted by many social media influencers and celebrities as a "miracle" weight loss drug. The sensationalization of the drug for weight loss purposes has resulted in an Ozempic shortage for diabetes patients who need the drug. Lawyers for the plaintiffs alleged medical negligence and professional liability by physicians who allegedly prescribed the drug knowing that it had not been approved by government regulators for strictly weight loss purposes, and without adequate warnings of ALL the potential medical side effects. Novo Nordisk says the company's clinical trial and post-marketing safety data did not show that the medication led to aspiration but noted that warning labels on the product do warn of delayed emptying of the stomach and possible related gastrointestinal side effects. Warning labels on Ozempic have always listed vomiting and abdominal pain as possible side effects. The prescribing information section of the Ozempic information